Zobrazeno 1 - 10
of 55
pro vyhledávání: '"M. J. Hawkins"'
Autor:
M. J. Hawkins, Mark R. Green, Sergei V. Orlov, P. Bhar, G. M. Manikhas, A. M. Makhson, Boris V. Afanasyev
Publikováno v:
Annals of Oncology. 17:1263-1268
Background: Abraxane® (ABI-007) is a novel 130-nm, albumin-bound (nab™) particle form of paclitaxel designed to utilize endogenous albumin pathways to increase intratumor concentrations of the active drug. This multicenter phase II study was desig
Autor:
M. J. Hawkins
Publikováno v:
JOM. 50:46-50
Cobalt is designated as a minor metal in the marketplace. Apart from a few exceptions, it is produced as a by-product of either nickel or copper and is used in a wide range of specialist applications. This article outlines a number of the processes u
Publikováno v:
Warship 2004: Littoral Warfare & The Expeditionary Force.
Autor:
P, Bhargava, J L, Marshall, W, Dahut, N, Rizvi, N, Trocky, J I, Williams, H, Hait, S, Song, K J, Holroyd, M J, Hawkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(12)
A Phase I study of squalamine, a novel antiangiogenic agent originally isolated from the dogfish shark Squalus acanthias, was conducted in patients with advanced cancers to: (a) determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT)
Autor:
H X, Chen, J L, Marshall, E, Ness, R R, Martin, B, Dvorchik, N, Rizvi, J, Marquis, M, McKinlay, W, Dahut, M J, Hawkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(4)
GEM231 is a mixed-backbone oligonucleotide targeting the regulatory subunit alpha of type I protein kinase A, which plays an important role in growth and maintenance of malignancies. Preclinically, GEM231 inhibited human cancer xenografts either alon
Autor:
N A, Rizvi, C H, Spiridonidis, T H, Davis, P, Bhargava, J L, Marshall, W, Dahut, M, Figuera, M J, Hawkins
Publikováno v:
Seminars in oncology. 26(5 Suppl 16)
Docetaxel and gemcitabine have been shown to be active as single agents in a variety of solid tumors. These two agents have been studied in combination with several different treatment schedules. Two phase I studies used a novel 2-week administration
Autor:
P, Bhargava, J L, Marshall, N, Rizvi, W, Dahut, J, Yoe, M, Figuera, K, Phipps, V S, Ong, A, Kato, M J, Hawkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(8)
A Phase I study of angiogenesis inhibitor TNP-470 was conducted in patients with advanced cancer. TNP-470 (25-235 mg/m2) was administered i.v. over 4 h once a week to patients who had solid tumors refractory to the best available treatment or with a
Autor:
N A, Rizvi, J L, Marshall, W, Dahut, E, Ness, J A, Truglia, G, Loewen, G M, Gill, E H, Ulm, R, Geiser, D, Jaunakais, M J, Hawkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(7)
LGD1069 [Targretin; 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl) propenyl] benzoic acid] is a novel synthetic retinoid X receptor-selective retinoid that has been recently identified. The goals of this study were to determine the saf
Autor:
J L, Marshall, A, Wellstein, J, Rae, R J, DeLap, K, Phipps, J, Hanfelt, M K, Yunmbam, J X, Sun, K L, Duchin, M J, Hawkins
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 3(12 Pt 1)
Tumor angiogenesis is critically important to tumor growth and metastasis. We have shown that pentosan polysulfate (PPS) is an effective inhibitor of heparin-binding growth factors in vitro and can effectively inhibit the establishment and growth of
Autor:
Mark A. Socinski, M. J. Hawkins, A. Makhson, P. Bhar, M. Georgy, S. Cheporov, P. Yablonsky, O. Sergey
Publikováno v:
European Journal of Cancer Supplements. 5:376-377